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Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related death. Developing minimally invasive techni-
ques that can diagnose NSCLC, particularly at an early stage, may improve its outcome. Using microarray platforms, we
previously identified 12 microRNAs (miRNAs) the aberrant expressions of which in primary lung tumors are associated
with early-stage NSCLC. Here, we extend our previous research by investigating whether the miRNAs could be used as
potential plasma biomarkers for NSCLC. We initially validated expressions of the miRNAs in paired lung tumor tissues and
plasma specimens from 28 stage I NSCLC patients by real-time quantitative reverse transcription PCR, and then evaluated
diagnostic value of the plasma miRNAs in a cohort of 58 NSCLC patients and 29 healthy individuals. The altered miRNA
expressions were reproducibly confirmed in the tumor tissues. The miRNAs were stably present and reliably measurable
in plasma. Of the 12 miRNAs, five displayed significant concordance of the expression levels in plasma and the corre-
sponding tumor tissues (all r40.850, all Po0.05). A logistic regression model with the best prediction was defined on the
basis of the four genes (miRNA-21,- 126,- 210, and 486-5p), yielding 86.22% sensitivity and 96.55% specificity in distin-
guishing NSCLC patients from the healthy controls. Furthermore, the panel of miRNAs produced 73.33% sensitivity and
96.55% specificity in identifying stage I NSCLC patients. In addition, the genes have higher sensitivity (91.67%) in
diagnosis of lung adenocarcinomas compared with squamous cell carcinomas (82.35%) (Po0.05). Altered expressions of
the miRNAs in plasma would provide potential blood-based biomarkers for NSCLC.
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Non-small-cell lung cancer (NSCLC) is the most common
type of lung cancer and the number-one cancer killer in the
United States and worldwide. NSCLC mainly consists of
two major histological types: adenocarcinoma (AC) and
squamous cell carcinoma (SCC). The disease is frequently
diagnosed at advanced stages, resulting in an overall 5-year
survival rate of about 14%.
1 Conversely, the 5-year survival
rate in stage I NSCLC patients who have received effective
treatments can be as high as 83%.
1 Therefore, finding NSCLC
earlier may reduce the mortality.
1 The sensitivity of chest
X-ray and sputum cytology for early detection of NSCLC is
low.
2,3 Bronchoscopy excels at detecting centrally occurring
lung tumors. However, it is invasive.
4 Although CT provides
excellent anatomic information and can noninvasively detect
NSCLC earlier at small size, the improved sensitivity is
associated with over-diagnosis.
1–5 Therefore, developing
minimally invasive techniques by taking advantage of recent
developments in molecular genetics for diagnosis of early
stage NSCLC is clinically important. Blood plasma is ob-
viously preferred choice for development of such diagnostic
markers. Numerous tumor-specific molecular alterations
have been identified in plasma/serum and shown the po-
tential as biomarkers in patients with lung cancers.
5,6 How-
ever, none of the tested markers thus far had sufficiently
achieved the required characteristics for diagnosis of NSCLC.
MicroRNAs (miRNAs) open up a new field for molecular
diagnosis of cancer.
7–13 Accumulating reports suggest
that circulating miRNAs are present in blood and have the
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lung cancer.
14,15 For example, serum miRNA signatures were
recently identified that could predict survival of NSCLC
patients.
16 Although the measurement of miRNA expressions
in plasma/serum has been postulated as a promising
approach in diagnosing lung cancer, the concept requires
further investigations to demonstrate its potential clinical
application.
Using microarray platforms, we recently identified 12
miRNAs the abnormal expressions of which in lung tumor
tissues were associated with early-stage NSCLC.
17–19 Here, we
extended our previous research by investigating whether the
miRNAs could be detected in plasma and used as minimally
invasive biomarkers for NSCLC. We first confirmed the ex-
pressions of the miRNAs in paired surgical tissue and plasma
specimens from an independent NSCLC cases by using
real-time quantitative reverse transcription PCR (Real-time
qRT-PCR). We then examined plasma expressions of the
miRNAs in a cohort of 58 NSCLC patients and 29 healthy
subjects to assess the diagnostic value for NSCLC. The study
shows that altered expressions of the miRNAs in plasma
might provide potential blood-based biomarkers for NSCLC.
MATERIALS AND METHODS
Patients and Clinical Specimens
The study was divided into two phases. In the first phase, we
determined whether the stage I NSCLC-associated miRNAs
the aberrant expressions of which could be confirmed in
independent surgical tissues, and whether the miRNAs were
present in plasma and their changes in plasma were consistent
with those in the corresponding tumors. To this end, we
obtained the paired lung tumor tissues and noncancerous
lung tissues and plasma specimens of 28 stage I NSCLC pa-
tients (Table 1) from Baltimore VA Maryland Health Care
System (BVAMHCS) and University of Maryland Medical
Center (UMMC). The cohort consisted of 18 male and 10
female, 21 white American and seven African American. Their
ages ranged from 46 to 79 years. In total, 14 tumors were
classified as AC and 14 as SCC. Smoking pack-years of the
cases were 38±27. Furthermore, blood samples were collected
from 28 age-, race-, gender-, and smoking status-matched
healthy individuals, and served as control specimens to assess
changes of the miRNAs in plasma of the cancer patients.
Sample collection was done in accordance with the protocols
approved by the Institutional Review Boards (IRBs) of
BVAMHCS and University of Maryland Baltimore.
Blood specimens of the cancer cases were collected before the
induction of anesthesia, before surgery. None of the patients
received preoperative adjuvant chemotherapy or radiotherapy.
The second phase of the study was to evaluate the
diagnostic value of the miRNAs for NSCLC in plasma. We
obtained blood samples from BVAMHCS, UMMC, and NCI-
Cooperative Human Tissue Network under the IRB proto-
cols. The specimens were collected from 58 NSCLC patients
with various stages and histological types and 29 healthy
individuals (Table 2). Among the cancer patients, 29 were
African American and 29 were Caucasian and 20 patients
were female and 38 were male. In total, 15 had stage I
NSCLC, 15 with stage II, 12 with stage III, and 16 with stage IV.
Histological diagnosis was made on bronchoscopic biopsy
specimens and thoracotomy according to the World Health
Organization (WHO) categories.
20,21 The NSCLC stage
classification was based on WHO classification and the
International Association for the Study of Lung Cancer
staging system. There were no significant differences of age,
race, gender, and smoking status between the NSCLC
patients and healthy individuals. Peripheral blood (10ml) was
drawn from the subjects using standardized phlebotomy
procedures in BD Vacutainer spray-coated K2EDTA Tubes
(BD, Franklin Lakes, NJ, USA). The blood samples from
cancer patients were collected at the time of initial consul-
tation, before definitive surgical management and/or adjuvant
therapy. The specimens were processed within 2h of collection
by centrifugation at 1300 g at for 10min 41C. Plasma was
transferred to a fresh tube and stored at  801Cu n t i lu s e .
RNA Isolation
RNA was extracted from the tissue specimens by using a
mirVana miRNA Isolation Kit (Ambion, Austin, TX, USA) as
described in our previous study.
17,18 The mirVana miRNA
Table 1 Demographic and clinical characteristics of a cohort of
28 stage I NSCLC cases and 28 healthy individuals
28 NSCLC cases 28 Healthy smokers
Age, median (s.d.) 65.8 (6.9) 67 (6.4)
Sex
Female 10 (35.7%) 10 (35.7%)
Male 18 (64.3%) 18 (64.3%)
Race
African American 7 (25%) 7 (25%)
White 21 (75%) 21 (75%)
Smoking status
Pack-years, median (s.d.) 35.3 (23.2) 35.8 (25.8)
Stage
All are stage I 28 (100%)
Histological types
AC 14 (50%)
SCC 14 (50%)
Abbreviations: AC, adenocarcinoma; NSCLC, non-small-cell lung cancer; SCC,
squamous cell carcinoma.
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plasma according to the manufacturer’s instructions. Briefly,
350ml plasma was diluted with two volumes of Lysis/Binding
Solution (Ambion). miRNA homogenate additive, in
volumes of 1/10, was then added in each aliquot. An equal
volume of acid/phenol/chloroform (Ambion) was added to
each aliquot. The resulting solutions were spun for 10min at
10000 g, and then passed through a mirVana column in
sequential 700-ml aliquots. 20ng of eluted RNA were pre-
treated with one unit of DNase (Invitrogen Corporation,
Carlsbad, CA, USA) and 0.38ml of RNase inhibitor
(Invitrogen Corporation). RNA’s purity and concentration
were determined from OD260/280 readings using a dual
beam UV spectrophotometer (Eppendorf AG, Hamburg,
Germany). Integrity of RNA was determined by using a
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA,
USA). RNA (with an RNA integrity number 46) underwent
in further analysis.
Quantification of miRNA Expression by qRT-PCR
The reverse transcription (RT) reaction was carried out with
TaqMan MicroRNA RT Kit (Applied Biosystems) according
to the manufacture’s instruction. An amount of 1.33mlo f
cDNA solution was amplified in 20ml of mixture. Quanti-
tative PCR was then performed on a Bio-Red IQ5 Multi-
color RT-PCR Detection System (Bio-Red, Hercules, CA,
USA). All assays were undertaken in triplicates, and one
no-template control and two interplate controls were carried
along in each experiment. Expression levels of the miRNAs
were calculated using comparative cycle threshold (Ct)
method.
17–19 Ct values of the target miRNAs were normalized
in relation to that of miR-16. As explained later, miR-16
was used as an internal control gene. The fold change was
calculated using the equation 2 DDCt.
Selection of Internal Control Gene for Quantification of
Plasma miRNAs
RNA was first purified from plasma of 20 NSCLC patients
and 20 healthy subjects. Synthesized Caenorhabditis elegans
miRNA, cel-miR-238 (Integrated DNA Technologies,
Coralville, IA, USA) that did not exist in the human genomes,
was spiked into each RNA sample with a concentration of
100fmol/ml. qRT-PCR was undertaken in the same amount of
RNA of each sample to determine Ct values of miR-16,
RNU6B, and cel-miR-238. Ct values of miR-16 and RNU6B
were compared with that of cel-miR-238 that was used to
normalize the difference of experimental efficiency among
different samples. To further evaluate the stability of miR-16
and RNU6B in plasma, plasma from five healthy individuals
was first incubated with an equal volume of 2  denaturing
solution (Ambion) to inhibit endogenous RNase activity. The
synthesized cel-miR-238 was spiked into each sample, which
was subsequently divided into three parts. The first aliquot of
each sample was processed for RNA extraction on day 1. The
last two aliquots were stored in 41Cf o r3a n d7d a y s ,
respectively, before being processed for RNA isolation. The Ct
values of the two human endogenous genes and cel-miR-238
were simultaneously determined by qRT-PCR.
Specificity and Sensitivity of qRT-PCR Assay for
Quantification of the miRNAs
Plasma was obtained from 10 healthy individuals and divided
into four parts in 350ml for each, respectively. The first ali-
quot from each specimen was processed on day 1 for isolating
RNA, whereas others were stored at  201C and processed on
day 3, 7, and 30. qRT-PCR was performed in the RNA
samples to determine whether the miRNAs were stably pre-
sent and reproducibly detectable in plasma. To further assess
stability of plasma miRNAs, plasma specimens from another
five healthy subjects were split in three parts, respectively. The
first two parts of each sample were incubated with RNase A
(Qiagen) at different concentrations (0.1 and 1mg/ml) for
24h, respectively. The third part of each specimen was treated
and served as controls. In addition, the synthesized cel-miR-
238 was spiked into the plasma samples treated with RNase A
(Qiagen) at different concentrations and the specimens
without the treatment. The expressions of the endogenous
Table 2 Demographic and clinical characteristics of an
independent cohort of 58 NSCLC cases and 29 healthy
individuals
58 NSCLC cases 29 Healthy
subjects
24 SCC
patients
34 AC
patients
Age, median (s.d.) 67.4 (8.7) 68 (8.2) 66 (7.8)
Sex
Female 9 (37.5%) 11 (32.3%) 10 (34.5%)
Male 15 (62.5%) 23 (67.7%) 19 (65.5%)
Race
African American 12 (50%) 16 (47.1%) 7 (24.1%)
White 12 (50%) 18 (52.9%) 22 (75.9%)
Smoking status
Pack-years, median (s.d.) 34.6 (27.8) 30.6 (21.1) 30.4 (28.3)
Stage
I 6 (25%) 9 (26.6%)
II 7 (29.2%) 8 (23.5%)
III 6 (25%) 6 (17.6%)
IV 5 (20.8%) 11 (32.3%)
Abbreviations: AC, adenocarcinoma; NSCLC, non-small-cell lung cancer; SCC,
squamous cell carcinoma.
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by qRT-PCR in parallel. Moreover, plasma of another five
healthy subjects was divided into three aliquots. The first
aliquot of each sample was subjected to five repeated cycles of
freeze thawing, whereas other two aliquots were stored in
 801C freezer for 3 and 7 days, respectively. Expression of the
endogenous miRNAs was also measured in these specimens.
To determine specificity of qRT-PCR assay for quantification
of miRNAs in plasma, the synthesized cel-miR-238 was
diluted in RNA isolated from five denatured plasma speci-
mens by 10 orders of magnitude, respectively. qRT-PCR with
primers specific to cel-miR-238 was performed in the sam-
ples. The plasma samples that were not spiked with the
synthesized cel-miR-238 were also tested in parallel and used
as controls. Furthermore, to assess the ability of qRT-PCR for
specifically amplifying human miRNA genes, two members
of a human miR-486 family, miR-486-3p and miR-486-5p,
were synthetically generated (Integrated DNA Technologies).
The synthesized miR-486 variants were diluted in DEPC
water and then polyadenylated and reversely transcribed.
Each of the miR-486 variants was subjected to two
independent qRT-PCR reactions, wherein each reaction there
were PCR primers specific to only one of the two variants. To
determine the sensitivity and dynamic range of qRT-PCR
for quantification of the plasma miRNAs, RNA was first
extracted from plasma of five healthy individuals and then
diluted by 10 orders of magnitude in DEPC water. Expres-
sions of the 12 miRNAs were assessed by qRT-PCR in the
serially diluted samples. All the experiments were performed
in triplicate and repeated three times.
Statistical Analysis
To determine whether genes were statistically differentially
expressed between the paired tumor tissues and normal tis-
sues, we expected the acceptable number of false positives to
be 1.0, fold difference between the two types of samples at
2.0, s.d. of the gene measurements on the base-two loga-
rithmic scale at 0.7, and desired power at 0.9. Given 12
miRNAs needed to be evaluated, at least nine specimens for
each tissue type were required to achieve the statistical
criteria.
22 To define an optimal miRNA marker panel for
distinguishing cancer patients from normal controls, a case–
control study was designed that consisted of lung cancer cases
and cancer-free individuals. The area under receiver operat-
ing characteristic curve (AUC) of H0 (the null hypothesis)
was set at 0.5. H1 represented the alternative hypothesis;
accordingly, at least 28 subjects were required in each cate-
gory to show a minimum difference of interest between an
AUC of 0.75 versus an AUC of 0.5 with 80% power at the 5%
significance level.
23 Therefore, the two sets of cohorts of cases
and controls recruited in the present study provided enough
statistical power to analyze the miRNAs.
Pearson’s correlation analysis was applied to determine as-
sociation of miRNA expressions of miRNAs in tumor tissues
with those in the paired plasma specimens. The analysis was
also applied to assess relationship between plasma miRNA
expressions and demographic characteristics of the patients and
healthy individuals. Clinicopathological diagnoses were used as
reference standards to decide sensitivity and specificity of the
genes. The receiver–operator characteristic curve and AUC
analyses were used to determine accuracy of each miRNA and
cut-off value of each miRNA in a specimen with a given spe-
cificity rate.
24 Logistic regression models with constrained
parameters and similar to least absolute shrinkage and selection
operator were applied to select an optimal panel of potential
biomarkers.
25 All analyses, including correlation coefficient,
W i l c o x o nt e s t ,l o g i s t i cr e g r e s s i o n ,A N O V A ,a n dS t u d e n t ’ st-test,
were performed using log-transformed data. All P-values
shown were two sided, and a P-value of o0.05 was considered
statistically significant.
RESULTS
The Changes of the NSCLC-associated miRNAs were
Reproducibly Validated in an Independent Set of
Surgical Tissues
We previously used microarray-based techniques to analyze
primary tumor tissues and identified 12 miRNAs the
expression changes of which were associated with stage I
NSCLC. The miRNAs include miR-21, 126, 145, 139, 182,
200b, 205, 210, 375, 429, 486-5p, and 708. To determine
whether aberrations of the miRNAs could be confirmed by a
different approach in independent tumor tissues, we assessed
expressions of the miRNAs by qRT-PCR in 28 stage I NSCLC
tissue and the paired noncancerous lung tissue specimens. All
of the miRNAs displayed more than two2-fold higher or
lower expression in the tumor tissues, as compared with the
corresponding noncancerous tissues (all Po0.001) (Table 3).
The observations were consistent with the previous find-
ings,
17 suggesting that the identified miRNAs by microarray
platforms could be well confirmed by qRT-PCR in a different
set of surgical specimens.
Selection of an Internal Control Gene for Quantification
of Plasma miRNAs
To find an internal control that can reliably quantify ex-
pressions of the target miRNAs in plasma, we evaluated miR-
16 and RNU6B in plasma of NSCLC and healthy subjects for
the Ct values of qRT-PCR. The two genes have previously
been proposed as potential internal normalization controls
for miRNA quantification.
26 To normalize the difference of
experimental efficiency among different samples, we per-
formed qRT-PCR in the same amount of RNA or fixed
volume of RNA eluted from a given volume of starting plasma
(350ml). Furthermore, we compared Ct values of endogenous
miR-16 and RNU6B with that of spiked cel-miR-238.
No significant difference was observed on freshly prepared
plasma for Ct values of miR-16 (P¼0.464) and RNU6B
(P¼0.418) between cancer patients and healthy controls
(Supplementary Figure 1). We further measured the genes in
the samples prepared at different time points. Ct values of
Plasma microRNA markers for lung cancer
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days (P40.05, Supplementary Figure 2A). However, RNU6B
exhibited less stability than miR-16, because the Ct values
of RNU6B on the samples that were stored for 7 days
were significantly higher than that on the samples prepared
on day 1 (P¼0.03) (Supplementary Figure 2B). Furthermore,
mean Ct value of miR-16 was statistically lower than that of
RNU6B in the same RNA samples tested on day 1 (19.2±1.2
versus 29.6±2.9, Po0.05). Altogether, the observations
indicated that miR-16 displayed higher stability and abun-
dance than did RNU6B in plasma. Therefore, miR-16 was
used as the normalization control to determine expressions of
the 12 miRNAs in the present study.
The Expressions of the NSCLC-associated miRNAs were
Reliably Measurable in Plasma
To determine whether the 12 miRNAs are present in plasma,
we measured their expressions in plasma of 10 healthy
individuals by qRT-PCR. All tested miRNAs had r32 Ct values
in each sample, indicating that the miRNAs existed in plasma
and were readily detectable. We next investigated the stability of
the endogenous miRNAs in archived plasma samples. Aliquots
of the plasma specimens were stored at  201C for 1, 3, 7, and
30 days, respectively. Bioanalyzer showed that there was
increasing degradation of total RNA illustrated by gradually
decreased heights of 18S and 28S peaks from day 1 to day 30
(Supplementary Figure 3A). However, there was no effect on
expression levels of the miRNAs determined by qRT-PCR in
the same specimens (Supplementary Figure 3B). Because
plasma has high levels of RNase activity, we further measured
e x p r e s s i o n so ft h em i R N A si nt h es a m p l e st r e a t e dw i t ho r
without RNase A. The abundance of the endogenous miRNAs
in the plasma samples with the different treatments was
fairly equable (all P40.05). Conversely, the spiked synthesized
cel-miR-238 was almost not detected in the plasma samples
(Supplementary Figure 4). The observation suggests that the
endogenous miRNAs in plasma possess considerable resistance
to the enzymatic cleavage of RNase A. However, the synthesized
cel-miR-238 that was added in the samples was not resistant to
either endogenous RNase A or exogenous RNase A in human
plasma. In addition, aliquots of plasma subjected to five
repeated cycles of freeze thawing and those that were stored at
 801C for 3 and 7 days did not display different expressions of
the miRNAs. The findings suggest that the plasma miRNAs
have adequate resistance to freeze–thaw action. Altogether, the
12 endogenous miRNAs are present in a stable form and
consistently measurable in plasma.
To define specificity of qRT-PCR for quantification of
miRNAs in plasma, synthesized cel-miR-238 was mixed with
the total RNA isolated from denatured plasma specimens.
The cel-miR-238 was detectable in the mixed samples.
However, cel-miR-238 was not observed in the human RNA
that was not spiked with the synthesized miRNA. Further-
more, there was excellent linearity between the cel-miR-238
input and the Ct values of qRT-PCR. In addition, qRT-PCR
exhibited a dynamic range of at least eight orders of mag-
nitude, and was able to detect as low as 10 copies of the cel-
miR-238 in each reaction, and the correlation coefficient was
0.996 for the synthesized miRNA (Supplementary Figure 5).
To further determine whether qRT-PCR assay can specifically
amplify the target miRNAs, the synthetic miR-486-5p or
miR-486-3p was subjected to two independent qRT-PCR
reactions, wherein each reaction there were PCR primers
specific to only one of the two genes. Non-specific amplifi-
cation was found while amplification only of the appropriate
gene that matched the specific primers was observed (Supple-
mentary Figure 6). The findings imply that the qRT-PCR
assay is highly specific and can discriminate miRNAs that are
the members from the same gene family. Therefore, the
miRNAs could be specifically detected in plasma.
To determine the sensitivity of qRT-PCR assay for detection
of the 12 miRNA, RNA isolated from plasma was diluted in
DEPC water by 10 orders of magnitude and then tested
for expression of each miRNA. There was excellent linearity
between the RNA input and the Ct values for qRT-PCR.
Furthermore, the assay had a dynamic range of at least eight
orders of magnitude, and was capable of detecting as few as 10
copies of the miRNAs per PCR reaction, and the correlation
coefficient was at least 0.992 for the 12 miRNAs (Supplemen-
tary Figure 7). Taken together, the miRNAs could be accurately
and robustly measured in blood plasma by qRT-PCR.
Abnormal Expressions of Five miRNAs in Plasma were
Consistent with those in the Paired Tumors of Stage I
NSCLC Patients
To determine relationship of the miRNA expressions in plasma
with those in primary tumor tissues, the miRNAs were tested
Table 3 miRNAs differentially expressed in 28 stage I NSCLC
tissues versus the paired noncancerous lung tissue specimens
by qRT-PCR
miRNAs Log2 (fold)* (mean±s.d.) P-value
miR-21 2.67265789±0.26879567 0.00072756
miR-126  2.95674568±0.23674323 0.00028312
miR-145  2.46785613±0.20874515 0.00052668
miR-139  2.13567129±0.19585334 0.00015854
miR-182 2.21567349±0.29864376 0.00026994
miR-205 2.86871452±0.25647823 0.00057825
miR-200b 2.15668178±0.23456782 0.00032678
miR-210 2.32567489±0.30124675 0.00076148
miR-375 2.84519747±0.25784738 0.00057838
miR-429  2.00934864±0.30032546 0.00023757
miR-486-5p  2.85638753±0.27545613 0.00043221
miR-708 2.26721137±0.31145759 0.00054983
Abbreviation: NSCLC, non-small-cell lung cancer.
*Median fold changes were determined by Wilcoxon test of paired data.
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2 8a g e - ,r a c e - ,g e n d e r - ,a n ds m o k i n gs t a t u s - m a t c h e dh e a l t h y
individuals. A miRNA gene is considered to have positive
change when ratio of its expression level in plasma from cancer
patients versus that in pooled plasma of the matched normal
subjects was either Z2.0 or r0.5 (absolute fold change Z2.0).
Using the cut-off level, miR-21, 210, and 182 exhibited
increased plasma expressions in 50.00–63.64% cancer patients
whose tumors had elevated expressions of the same three genes
(Table 4). On the contrary, miR-126 and 486-5p displayed
decreased plasma expression levels in 59.09–68.18% cancer
patients whose tumors had reduced expressions of the two
miRNAs. Furthermore, Pearson’s correlation analysis showed
that there were significant correlations between the expression
levels of the five miRNAs in plasma and those in the paired
tumors (all rZ0.85, all Pr0.01). However, another seven
genes, including miR-139, 145, 205, 200b, 375, 429, and 708,
did not display considerable changes in plasma of the NSCLC
patients whose tumors showed either higher or lower expres-
sions of the genes, as compared with those in the plasma
samples of the healthy controls. These findings implied that
plasma samples and the corresponding primary cancer tissues
showed similar tendencies concerning the expressions of miR-
21, 126, 182, 210, and 486-5p. The level of the genes in plasma
might reflect those in the tumors of the same cancer patients.
Therefore, the five miRNAs could be candidate plasma bio-
markers for NSCLC and lead to the next step of the study.
A Panel of miRNAs was Optimized as Plasma-based
Biomarkers for NSCLC
To evaluate diagnostic value of the five miRNAs in plasma for
NSCLC, plasma expressions of the genes were measured by
qRT-PCR in a cohort of 58 NSCLC patients and 29 healthy
individuals. Overall, expression levels of miR-21, 210, and
182 in cancer patients were statistically higher than those in
healthy subjects (all Po0.001) (Supplementary Table 1). In
contrast, miR-126 and miR-486-5p were present at lower
plasma levels in NSCLC patients than in the healthy subjects
(all Po0.001). The individual miRNAs exhibited AUC values
of 0.662–0.878 in distinguishing NSCLC patients from the
healthy individuals, revealing 51.72–84.48% sensitivity and
65.52–82.76% specificity (Supplementary Table 2). On the
basis of the AUC values, a logistic regression model with the
best prediction was defined that consisted of miR-21, 126,
210, and 486-5p. As shown in Figure 1, the composite panel
of the four miRNAs produced 0.926 AUC that was higher
than those of individual genes used alone (all Po0.05).
Given a specificity of 96.55%, the four miRNAs used in
conjunction revealed a sensitivity of 86.22% in differentiating
NSCLC patients from the healthy subjects. Furthermore,
Pearson’s correlation analysis indicated that the estimated
correlations among expression levels of the four miRNAs
were low (all ro0.50, all P40.05), implying that plasma
Table 4 Prevalence of altered miRNA expressions in the paired
tumor and plasma samples from 28 stage I NSCLC patients
a
miRNAs No. of subjects with altered expressions of miRNA (%)
Tumor, no. positive (%) Plasma, no. positive (%)
b
miR-21 28/28, (100) 19/28, (67.86)
miR-126 28/28, (100) 18/28, (64.29)
miR-182 28/28, (100) 17/28, (60.71)
miR-210 28/28, (100) 16/28, (57.14)
miR-486-5p 28/28, (100) 20/28, (71.43)
Abbreviation: NSCLC, non-small-cell lung cancer.
aExpression of the miRNAs in each sample was calculated by using com-
parative cycle threshold (Ct) method with the equation 2 DDCt. Ct values of
the target miRNAs were normalized in relation to that of miR-16.
bA miRNA gene is considered to have positive change when ratio of its ex-
pression level in plasma from cancer patients versus that in pooled plasma
samples of the matched normal controls was either Z2.0 or r0.5 (absolute
fold change Z2.0).
Figure 1 Receiver–operator characteristic (ROC) curve analysis of
expression levels of the four miRNAs in plasma of 58 patients diagnosed
with NSCLC and 29 healthy individuals. The area under the ROC curve (AUC)
for each miRNA conveys its accuracy in differentiating NSCLC patients from
the healthy subjects in terms of sensitivity and specificity. The individual
genes produce 0.662–0.878 AUC values (a–d), being significantly lower
than 0.926 AUC by the four genes genes used in combination as a marker
panel (e) (all Po0.05).
Plasma microRNA markers for lung cancer
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other. The data further supported that the combined analyses
of the genes outperformed a single one used alone for
diagnosis of NSCLC.
The four miRNAs used in combination had higher diag-
nostic sensitivity in more advanced stages (II–IV) as com-
pared with stage I NSCLC (Po0.05) (Table 5). However,
combining the four genes still produced 73.33% sensitivity
and 96.55% specificity in distinguishing stage I NSLCLC
patients from the healthy subjects. In addition, the diagnostic
sensitivity of the genes used together was significantly higher
for ACs (91.67%) than SCCs of the lungs (82.35%)
(Po0.05). Finally, there was no association between the
changes of the genes with age, gender, ethnic group, and
smoking status of the participants (all P40.05).
DISCUSSION
In the present study, we reproducibly validated our pre-
viously identified NSCLC-associated miRNAs in independent
tumor tissues by using qRT-PCR assay. We further showed
that the miRNAs were stably present and readily measurable
in plasma. We finally demonstrated that a panel of plasma
miRNAs would provide potential biomarkers that could
differentiate NSCLC patients from healthy individuals.
Upregulation of miR-21 has been found in numerous
human cancers.
27–30 miR-21 was recently classed as an
oncomir the overexpression of which could lead to tumor
development and progression.
29 Furthermore, the measure-
ment of miR-21 expression in plasma might be useful in
diagnosis of pancreatic cancers.
31 In addition, elevated serum
miRNA-21 levels in patients with metastatic hormone-
refractory prostate cancer could be a predictive factor for the
efficacy of docetaxel-based chemotherapy.
32 Moreover, a high
correlation of miRNA expression level of a panel of six
miRNAs, including miR-21, was found between breast
tumors and paired sera.
33 Additionally, miR-21 was sig-
nificantly over-expressed in specimens of cancer patients
compared with those in normal controls. miR-21 could be
one of blood-based biomarkers for breast cancer diagnosis,
grading and prognosis.
33 The data produced from our
present study imply that plasma miR-21 could serve as a
biomarker for diagnosis of lung cancer. miR-486-5p was
found to be underexpressed in eight types of human tumors,
including lung cancer.
34 The observation from the current
study using plasma is consistent with the previous finding,
and further suggests that miR-486-5p might be a potential
plasma-based biomarker for lung cancer. miR-126 has been
considered as a tumor suppressor in human carcinogenesis,
and its decreased expression is associated with metastasis of
breast cancers.
35 Furthermore, the reduced expression of
miR-126 was recently found to be closely associated with
clinicopathological features of breast cancer.
33 Moreover, by
analyzing a miRNA profile of SCC samples of Chinese lung
cancer patients, Yang et al identified that miR-126 was one
of the miRNAs that were downregulated in the tumors
compared with noncancerous lung tissues.
36 Furthermore,
enforced expression of miR-126 in gastric cancer cells in-
hibited cell growth by inducing cell-cycle arrest in G0/G1
phase, migration and invasion in vitro, as well as tumor-
igenicity and metastasis in vivo. In addition, miR-126 might
have a tumor-suppressor role in tumorigenesis by targeting
an adapter protein, Crk.
37 Our current study shows that
measuring reduced plasma expression of miR-126 that could
distinguish NSCLC patients from control subjects. miR-210
can regulate the hypoxic response of tumor cells and tumor
growth.
38 Elevated expression of miR-210 was significantly
associated with aggressiveness of lymph node-negative,
estrogen receptor-positive human breast cancer.
10 Further-
more, increased miR-210 expressions in serum could be
useful as one of markers for patients with diffuse large B-cell
lymphoma and pancreatic ductal AC.
31,39 Our present
observation further suggests that miR-210 might be a
potential plasma marker for NSCLC.
Because tobacco use is the major cause of NSCLC, most of
the previously identified lung cancer-associated molecular
genetic changes are related to the smoking status.
1,5 The use
of such alterations as biomarkers might produce over-diag-
nosis. Interestingly, plasma expressions of the four miRNA
genes are independent of smoking pack-years of the parti-
cipants. Although our result appears to be promising, there
are several limitations in this study. First, because the sample
size of the two cohorts was too small and resulting sensitivity
(73.33%) was too low for diagnosis of stage I NSCLC. Fur-
ther launching the miRNAs in large cohorts and independent
studies is clearly required. Furthermore, the gene expressions
Table 5 Diagnostic performance of the composite panel of the
four miRNAs in a cohort of 58 NSCLC patients and 29 healthy
subjects
Sensitivity, % Specificity, %
All cases 86.22 (50/58) 96.55 (28/29)
Different histological types
SCC 82.35 (28/34) 96.55 (28/29)
AC 91.67 (22/24)
a 96.55 (28/29)
Cases with different stages
I 73.33 (11/15) 96.55 (28/29)
II 86.67 (13/15)
b 96.55 (28/29)
III 91.67 (11/12)
b 96.55 (28/29)
IV 93.75 (15/16)
b 96.55 (28/29)
Abbreviations: AC, adenocarcinoma; NSCLC, non-small-cell lung cancer; SCC,
squamous cell carcinoma.
aDifference of sensitivity of the four miRNAs used together in diagnosis of SCC
and AC, Po0.05.
bComparison of stage I with II, III, and IV, respectively, regarding diagnostic
sensitivity of the four miRNAs. All Po0.05.
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the lungs. However, due to the small size of the samples,
whether the miRNAs could be used as specific markers for
AC remains to be investigated. Second, the 12 candidate
miRNAs chosen in the present study were based on our
previous microarray analysis data on primary lung cancer.
17
We will evaluate lung tumor-associated miRNAs defined
from other groups to identify additional plasma-based
miRNAs that can be added to the current ones so that the
diagnostic efficacy of the approach could be improved. Third,
the plasma miRNA expressions were more related to ad-
vanced stages of NSCLC compared with stage I NSCLC,
suggesting the potential as prognostic markers for the disease.
However, we were not able to assess plasma expression
changes of the miRNAs before and after surgery, and their
prognostic value in predicting outcome of NSCLC in the
present study, because blood samples were only obtained
from the lung cancer cases before they received surgery, and
follow-up information of the patients was not yet available.
Although showing altered changes in tumor tissues, miR-
139, 145, 205, 200b, 375, 429, and 708 did not display ab-
normal plasma expressions in stage I lung cancer patients.
The explanations for the discrepancy remain unclear. One
possible reason might be that NSCLC develops from complex
and multistep processes. Although showing dysregulation
within lung tumors, the changes in plasma of the cancer-
related miRNAs might occur at comparable late stage of the
disease. Therefore, the genes could not show considerable
expression differences in plasma between patients with
early-stage NSCLC and healthy controls. However, future
investigation of possible mechanism underlies the dis-
crepancy is needed.
In conclusion, we demonstrated that the expressions of the
miRNAs identified from surgical tumor tissues could readily
and specifically be measured in plasma. More importantly,
detection of a panel of the miRNAs in plasma would
potentially be used as a minimally invasive diagnostic tool for
NSCLC, including ACs of the lungs. Nonetheless, further
validating the utility of the potential biomarker in an
independent cohort is required.
Supplementary Information accompanies the paper on the Laboratory
Investigation website (http://www.laboratoryinvestigation.org)
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